Loading…
The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial‐like head and neck carcinoma subtypes
Background We aimed at identifying molecular markers predictive of clinical outcome in patients with head and neck cancer based on the expression profile of cells showing epithelial‐like (EL) or mesenchymal‐like (ML) phenotypes. Materials and methods We analyzed the association between EL and ML cel...
Saved in:
| Published in: | Head & neck 2019-06, Vol.41 (6), p.1830-1845 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3533-cb848c5924792e7acb74bf829e969ec2dcbbc12d19ff94551fd3af04bcc2883c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3533-cb848c5924792e7acb74bf829e969ec2dcbbc12d19ff94551fd3af04bcc2883c3 |
| container_end_page | 1845 |
| container_issue | 6 |
| container_start_page | 1830 |
| container_title | Head & neck |
| container_volume | 41 |
| creator | Pavón, Miguel Angel Arroyo‐Solera, Irene León, Xavier Téllez‐Gabriel, Marta Virós, David Gallardo, Alberto Céspedes, Maria Virtudes Casanova, Isolda Lopez‐Pousa, Antonio Barnadas, Agustí Quer, Miquel Mangues, Ramón |
| description | Background
We aimed at identifying molecular markers predictive of clinical outcome in patients with head and neck cancer based on the expression profile of cells showing epithelial‐like (EL) or mesenchymal‐like (ML) phenotypes.
Materials and methods
We analyzed the association between EL and ML cells and migration, drug resistance, or tumor growth. The differential gene expression profile between cell types was used to build a model to stratify patients according to survival.
Results
EL cells were sensitive to cisplatin and cetuximab, showed low migration, and generated squamous differentiated tumors in mouse. A differential 93‐gene expression signature between ML and EL cells was used to build a three‐gene (EFS, GPX2, and SPRR1A) survival model by analyzing the RNA‐seq data of the TCGA‐HNSC project. Its prognostic value was confirmed in two independent cohorts.
Conclusion
EFS, GPX2, and SPRR1A are prognostic markers able to distinguish clinical outcome among subtypes sharing an EL phenotype. |
| doi_str_mv | 10.1002/hed.25623 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179376519</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2179376519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-cb848c5924792e7acb74bf829e969ec2dcbbc12d19ff94551fd3af04bcc2883c3</originalsourceid><addsrcrecordid>eNp1kc9OFjEUxRujEUQXvoBp4kYSBvpn_nVJ8ANMSCSAibtJ27llCp12bGfEb-cj-BA-mU9i4YONiat7c_O755zkIPSWkn1KCDsYoN9nVc34M7RNiWgKwsvm-f1e8oKTptxCr1K6IYTwumQv0RYndcV4S7bR76sBsA6jsh56vCTAweDV8eUePjn_yvaw9D2-PL-4oIcYfkwRUrLB54fF9bi3abb-erFpwEZ-D1EqB9jEMOIphIi1s95q6XBY5mwBWI7BX2OY7DyAs9L9-fnL2VvAA8j-wcmDvsVaRm19GCVOi5rXE6TX6IWRLsGbx7mDvhyvro5Oi7PPJ5-ODs8KzSvOC63astWVYGUjGDRSq6ZUpmUCRC1As14rpSnrqTBGlFVFTc-lIaXSmrUt13wHfdjoTjF8WyDN3WiTBuekh7CkjtFG8KauqMjo-3_Qm7BEn9N1jLGcgxDKM7W7oXQMKUUw3RTtKOO6o6S7r67L1XUP1WX23aPiosZ8fSKfusrAwQa4sw7W_1fqTlcfN5J_AZu5pLU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2228480013</pqid></control><display><type>article</type><title>The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial‐like head and neck carcinoma subtypes</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Pavón, Miguel Angel ; Arroyo‐Solera, Irene ; León, Xavier ; Téllez‐Gabriel, Marta ; Virós, David ; Gallardo, Alberto ; Céspedes, Maria Virtudes ; Casanova, Isolda ; Lopez‐Pousa, Antonio ; Barnadas, Agustí ; Quer, Miquel ; Mangues, Ramón</creator><creatorcontrib>Pavón, Miguel Angel ; Arroyo‐Solera, Irene ; León, Xavier ; Téllez‐Gabriel, Marta ; Virós, David ; Gallardo, Alberto ; Céspedes, Maria Virtudes ; Casanova, Isolda ; Lopez‐Pousa, Antonio ; Barnadas, Agustí ; Quer, Miquel ; Mangues, Ramón</creatorcontrib><description>Background
We aimed at identifying molecular markers predictive of clinical outcome in patients with head and neck cancer based on the expression profile of cells showing epithelial‐like (EL) or mesenchymal‐like (ML) phenotypes.
Materials and methods
We analyzed the association between EL and ML cells and migration, drug resistance, or tumor growth. The differential gene expression profile between cell types was used to build a model to stratify patients according to survival.
Results
EL cells were sensitive to cisplatin and cetuximab, showed low migration, and generated squamous differentiated tumors in mouse. A differential 93‐gene expression signature between ML and EL cells was used to build a three‐gene (EFS, GPX2, and SPRR1A) survival model by analyzing the RNA‐seq data of the TCGA‐HNSC project. Its prognostic value was confirmed in two independent cohorts.
Conclusion
EFS, GPX2, and SPRR1A are prognostic markers able to distinguish clinical outcome among subtypes sharing an EL phenotype.</description><identifier>ISSN: 1043-3074</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.25623</identifier><identifier>PMID: 30652380</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Cell migration ; Cisplatin ; Clinical outcomes ; Drug resistance ; EFS ; epithelial‐like ; Gene expression ; gene‐expression profile ; GPX2 ; Head & neck cancer ; head and neck cancer ; mesenchymal‐like ; Mesenchyme ; Monoclonal antibodies ; Phenotypes ; prognosis ; Ribonucleic acid ; RNA ; SPRR1A ; survival ; Targeted cancer therapy ; Tumors</subject><ispartof>Head & neck, 2019-06, Vol.41 (6), p.1830-1845</ispartof><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-cb848c5924792e7acb74bf829e969ec2dcbbc12d19ff94551fd3af04bcc2883c3</citedby><cites>FETCH-LOGICAL-c3533-cb848c5924792e7acb74bf829e969ec2dcbbc12d19ff94551fd3af04bcc2883c3</cites><orcidid>0000-0001-6286-630X ; 0000-0001-7992-8626</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30652380$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pavón, Miguel Angel</creatorcontrib><creatorcontrib>Arroyo‐Solera, Irene</creatorcontrib><creatorcontrib>León, Xavier</creatorcontrib><creatorcontrib>Téllez‐Gabriel, Marta</creatorcontrib><creatorcontrib>Virós, David</creatorcontrib><creatorcontrib>Gallardo, Alberto</creatorcontrib><creatorcontrib>Céspedes, Maria Virtudes</creatorcontrib><creatorcontrib>Casanova, Isolda</creatorcontrib><creatorcontrib>Lopez‐Pousa, Antonio</creatorcontrib><creatorcontrib>Barnadas, Agustí</creatorcontrib><creatorcontrib>Quer, Miquel</creatorcontrib><creatorcontrib>Mangues, Ramón</creatorcontrib><title>The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial‐like head and neck carcinoma subtypes</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
We aimed at identifying molecular markers predictive of clinical outcome in patients with head and neck cancer based on the expression profile of cells showing epithelial‐like (EL) or mesenchymal‐like (ML) phenotypes.
Materials and methods
We analyzed the association between EL and ML cells and migration, drug resistance, or tumor growth. The differential gene expression profile between cell types was used to build a model to stratify patients according to survival.
Results
EL cells were sensitive to cisplatin and cetuximab, showed low migration, and generated squamous differentiated tumors in mouse. A differential 93‐gene expression signature between ML and EL cells was used to build a three‐gene (EFS, GPX2, and SPRR1A) survival model by analyzing the RNA‐seq data of the TCGA‐HNSC project. Its prognostic value was confirmed in two independent cohorts.
Conclusion
EFS, GPX2, and SPRR1A are prognostic markers able to distinguish clinical outcome among subtypes sharing an EL phenotype.</description><subject>Cell migration</subject><subject>Cisplatin</subject><subject>Clinical outcomes</subject><subject>Drug resistance</subject><subject>EFS</subject><subject>epithelial‐like</subject><subject>Gene expression</subject><subject>gene‐expression profile</subject><subject>GPX2</subject><subject>Head & neck cancer</subject><subject>head and neck cancer</subject><subject>mesenchymal‐like</subject><subject>Mesenchyme</subject><subject>Monoclonal antibodies</subject><subject>Phenotypes</subject><subject>prognosis</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>SPRR1A</subject><subject>survival</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>1043-3074</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kc9OFjEUxRujEUQXvoBp4kYSBvpn_nVJ8ANMSCSAibtJ27llCp12bGfEb-cj-BA-mU9i4YONiat7c_O755zkIPSWkn1KCDsYoN9nVc34M7RNiWgKwsvm-f1e8oKTptxCr1K6IYTwumQv0RYndcV4S7bR76sBsA6jsh56vCTAweDV8eUePjn_yvaw9D2-PL-4oIcYfkwRUrLB54fF9bi3abb-erFpwEZ-D1EqB9jEMOIphIi1s95q6XBY5mwBWI7BX2OY7DyAs9L9-fnL2VvAA8j-wcmDvsVaRm19GCVOi5rXE6TX6IWRLsGbx7mDvhyvro5Oi7PPJ5-ODs8KzSvOC63astWVYGUjGDRSq6ZUpmUCRC1As14rpSnrqTBGlFVFTc-lIaXSmrUt13wHfdjoTjF8WyDN3WiTBuekh7CkjtFG8KauqMjo-3_Qm7BEn9N1jLGcgxDKM7W7oXQMKUUw3RTtKOO6o6S7r67L1XUP1WX23aPiosZ8fSKfusrAwQa4sw7W_1fqTlcfN5J_AZu5pLU</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Pavón, Miguel Angel</creator><creator>Arroyo‐Solera, Irene</creator><creator>León, Xavier</creator><creator>Téllez‐Gabriel, Marta</creator><creator>Virós, David</creator><creator>Gallardo, Alberto</creator><creator>Céspedes, Maria Virtudes</creator><creator>Casanova, Isolda</creator><creator>Lopez‐Pousa, Antonio</creator><creator>Barnadas, Agustí</creator><creator>Quer, Miquel</creator><creator>Mangues, Ramón</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6286-630X</orcidid><orcidid>https://orcid.org/0000-0001-7992-8626</orcidid></search><sort><creationdate>201906</creationdate><title>The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial‐like head and neck carcinoma subtypes</title><author>Pavón, Miguel Angel ; Arroyo‐Solera, Irene ; León, Xavier ; Téllez‐Gabriel, Marta ; Virós, David ; Gallardo, Alberto ; Céspedes, Maria Virtudes ; Casanova, Isolda ; Lopez‐Pousa, Antonio ; Barnadas, Agustí ; Quer, Miquel ; Mangues, Ramón</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-cb848c5924792e7acb74bf829e969ec2dcbbc12d19ff94551fd3af04bcc2883c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cell migration</topic><topic>Cisplatin</topic><topic>Clinical outcomes</topic><topic>Drug resistance</topic><topic>EFS</topic><topic>epithelial‐like</topic><topic>Gene expression</topic><topic>gene‐expression profile</topic><topic>GPX2</topic><topic>Head & neck cancer</topic><topic>head and neck cancer</topic><topic>mesenchymal‐like</topic><topic>Mesenchyme</topic><topic>Monoclonal antibodies</topic><topic>Phenotypes</topic><topic>prognosis</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>SPRR1A</topic><topic>survival</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pavón, Miguel Angel</creatorcontrib><creatorcontrib>Arroyo‐Solera, Irene</creatorcontrib><creatorcontrib>León, Xavier</creatorcontrib><creatorcontrib>Téllez‐Gabriel, Marta</creatorcontrib><creatorcontrib>Virós, David</creatorcontrib><creatorcontrib>Gallardo, Alberto</creatorcontrib><creatorcontrib>Céspedes, Maria Virtudes</creatorcontrib><creatorcontrib>Casanova, Isolda</creatorcontrib><creatorcontrib>Lopez‐Pousa, Antonio</creatorcontrib><creatorcontrib>Barnadas, Agustí</creatorcontrib><creatorcontrib>Quer, Miquel</creatorcontrib><creatorcontrib>Mangues, Ramón</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pavón, Miguel Angel</au><au>Arroyo‐Solera, Irene</au><au>León, Xavier</au><au>Téllez‐Gabriel, Marta</au><au>Virós, David</au><au>Gallardo, Alberto</au><au>Céspedes, Maria Virtudes</au><au>Casanova, Isolda</au><au>Lopez‐Pousa, Antonio</au><au>Barnadas, Agustí</au><au>Quer, Miquel</au><au>Mangues, Ramón</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial‐like head and neck carcinoma subtypes</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2019-06</date><risdate>2019</risdate><volume>41</volume><issue>6</issue><spage>1830</spage><epage>1845</epage><pages>1830-1845</pages><issn>1043-3074</issn><eissn>1097-0347</eissn><abstract>Background
We aimed at identifying molecular markers predictive of clinical outcome in patients with head and neck cancer based on the expression profile of cells showing epithelial‐like (EL) or mesenchymal‐like (ML) phenotypes.
Materials and methods
We analyzed the association between EL and ML cells and migration, drug resistance, or tumor growth. The differential gene expression profile between cell types was used to build a model to stratify patients according to survival.
Results
EL cells were sensitive to cisplatin and cetuximab, showed low migration, and generated squamous differentiated tumors in mouse. A differential 93‐gene expression signature between ML and EL cells was used to build a three‐gene (EFS, GPX2, and SPRR1A) survival model by analyzing the RNA‐seq data of the TCGA‐HNSC project. Its prognostic value was confirmed in two independent cohorts.
Conclusion
EFS, GPX2, and SPRR1A are prognostic markers able to distinguish clinical outcome among subtypes sharing an EL phenotype.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>30652380</pmid><doi>10.1002/hed.25623</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0001-6286-630X</orcidid><orcidid>https://orcid.org/0000-0001-7992-8626</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2019-06, Vol.41 (6), p.1830-1845 |
| issn | 1043-3074 1097-0347 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179376519 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Cell migration Cisplatin Clinical outcomes Drug resistance EFS epithelial‐like Gene expression gene‐expression profile GPX2 Head & neck cancer head and neck cancer mesenchymal‐like Mesenchyme Monoclonal antibodies Phenotypes prognosis Ribonucleic acid RNA SPRR1A survival Targeted cancer therapy Tumors |
| title | The combined use of EFS, GPX2, and SPRR1A expression could distinguish favorable from poor clinical outcome among epithelial‐like head and neck carcinoma subtypes |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T04%3A47%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20combined%20use%20of%20EFS,%20GPX2,%20and%20SPRR1A%20expression%20could%20distinguish%20favorable%20from%20poor%20clinical%20outcome%20among%20epithelial%E2%80%90like%20head%20and%20neck%20carcinoma%20subtypes&rft.jtitle=Head%20&%20neck&rft.au=Pav%C3%B3n,%20Miguel%20Angel&rft.date=2019-06&rft.volume=41&rft.issue=6&rft.spage=1830&rft.epage=1845&rft.pages=1830-1845&rft.issn=1043-3074&rft.eissn=1097-0347&rft_id=info:doi/10.1002/hed.25623&rft_dat=%3Cproquest_cross%3E2179376519%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3533-cb848c5924792e7acb74bf829e969ec2dcbbc12d19ff94551fd3af04bcc2883c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2228480013&rft_id=info:pmid/30652380&rfr_iscdi=true |